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Summary 
People with Down syndrome, a frequent genetic disorder in humans, have increased risk of 
health problems associated with this condition. One clinical feature of Down syndrome is the 
increased prevalence and severity of periodontal disease in comparison with the general 
population. Since saliva plays an important role in maintaining oral health, in the present study 
the salivary proteome of Down syndrome subjects was investigated to explore modifications 
with respect to healthy subjects. Whole saliva of 36 Down syndrome subjects, divided in the 
age groups 10-17 yrs and 18-50 yrs, was analyzed by a top-down proteomic approach, based on 
the HPLC-ESI-MS analysis of the intact proteins/peptides, and the qualitative and quantitative 
profiles were compared with sex and age-matched control groups. The results showed the 
following interesting features: i) differently from controls, in Down syndrome subjects the 
concentration of the major salivary proteins of gland origin did not increase with age; as a 
consequence concentration of acidic proline rich proteins and S cystatins was found 
significantly reduced in older Down syndrome subjects with respect to matched controls; ii) 
levels of the antimicrobial -defensins 1 and 2 and histatins 3 and 5 were significantly 
increased in whole saliva of older Down syndrome subjects with respect to controls; iii) 
S100A7, S100A8 and S100A12 levels were significantly increased in whole saliva of Down 
syndrome subjects in comparison with controls. The increased level of S100A7 and S100A12 
may be of particular interest, as biomarker of the early onset Alzheimer’s disease, which is 
frequently associated with Down syndrome.  
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Introduction 
The Down syndrome (DS) is a frequent genetic disorder in humans characterized by premature 
aging (1). A clinical feature of people with DS is the increased prevalence and severity of 
periodontal disease compared with age-matched subjects of similar levels of intellectual 
impairment and compared with the general population (2). Common conditions observed in DS 
are marginal gingivitis, acute and subacute necrotizing gingivitis, advanced periodontitis, 
gingival recession and pocket formation (3,4). It is known that saliva plays an important role in 
maintaining oral and dental health, due to the presence of a variety of antimicrobial peptides 
mainly derived from gland secretion, oral epithelial cells and neutrophils (5). Several papers 
reported that neutrophils and T-lymphocyte function is impaired in people with DS (6-9). 
However, the salivary secretion of the antimicrobial LL-37 in young individuals with DS was 
found normal (10). A review of the literature (11, 12) reveals only sporadic and contradictory 
reports that attempt to explain the role of saliva in the oral health of subjects with DS, and on 
the whole information on the biochemical composition of their saliva is scarce. On the basis of 
the above information, in the present study we proposed to investigate the salivary proteome of 
DS subjects by an intact protein-based “top-down” approach. The spectrum of salivary peptides 
of DS subjects was compared to that of sex and age-matched healthy control groups in order to 
determine qualitative and quantitative differences. Interestingly, the results showed that several 
members of the S100A family, which possess different biological functions, and also described 
as potential markers of the Alzheimer Disease, were significantly increased in saliva of Down 
syndrome subjects with respect to controls.   
  
Experimental procedures 
All chemicals and reagents were of analytical grade and were purchased from Farmitalia-Carlo 
Erba, (Milan, Italy), Sigma Aldrich (St. Louis, MI, USA) and Merck (Damstadt, Germany). 
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Low-resolution HPLC-ESI-ion trap-MS measurements were carried out by a Surveyor HPLC 
system (ThermoFisher, San Jose, CA, USA) connected by a T splitter to a diode-array detector 
and to an LCQ Advantage mass spectrometer (ThermoFisher). The mass spectrometer was 
equipped with an ESI source. The chromatographic column was a Vydac (Hesperia, CA, USA) 
C8 column with 5 m particle diameter (column dimensions 150x2.1 mm). High-resolution 
HPLC-ESI-MS/MS experiments were carried out by an Ultimate 3000 Micro HPLC apparatus 
(Dionex, Sunnyvale, CA, USA) equipped with a FLM-3000-Flow manager module coupled to 
LTQ Orbitrap XL apparatus (ThermoFisher). A Zorbax 300SB-C8 column (3.5 m particle 
diameter; column dimension 1.0x150mm) was utilized for these experiments. 
Ethics statements and subjects under study  
The study protocol and written consent forms were approved by the Medical Ethics Committee 
of the Faculty of Medicine of the Catholic University of Rome (according to the instructions of 
the Declaration of Helsinki). The study protocol was explained to both parents and children, 
and informed written consent to participate in the study was obtained from a parent. Down 
syndrome subjects were enrolled at the Department of Surgery, Medical, Molecular, and 
Critical Area Pathology, University of Pisa and at the Institute of Pediatric Clinic of the Faculty 
of Medicine of the Catholic University of Rome. The 36 patients enrolled for the study were 
divided in two age-groups: 10-17 years (mean age ± SD: 12.6 ± 2.3; 3 females (F), 15 males 
(M)) and 18-50 years (mean age ± SD: 27.5 ± 8.6; 5F, 13M). The two control group comprised 
the same number of subjects: 10-17 years (mean age ± SD: 12.7 ± 2.3; 5F, 13M) and 18-50 
years (mean age ± SD: 27.6 ± 8.0; 11F, 7M).  
Sample collection  
Unstimulated whole saliva was collected according to a standard protocol. Donors did not eat 
or drink at least 2 h before the collection, which was performed in the morning between 10:00 
a.m. and 12:00 p.m. with a soft plastic aspirator. Saliva was transferred to a plastic tube in ice 
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bath and an acidic solution (0.2% 2,2,2-trifluoroacetic acid,TFA) was immediately added in 
1:1 v/v ratio. The solution was then centrifuged at 8000 g for 10 min at 4°C. The acidic 
supernatant was separated from the precipitate and either immediately analyzed by HPLC-ESI-
MS (100 L, corresponding to 50 L of saliva) or stored at – 80°C until the analysis.  
 HPLC-ESI-IT-MS analysis  
The following solutions were utilized for RP-HPLC-ESI-MS analysis: (eluent A) 0.056% (v/v) 
aqueous TFA and (eluent B) 0.05% (v/v) TFA in acetonitrile-water 80/20. The gradient applied 
for the analysis of saliva was linear from 0 to 55% of B in 40 min, and from 55% to 100% of B 
in 10 min, at a flow rate of 0.30 mL/min. For tryptic digests the gradient was from 0 to 65% of 
B in 40 min, and from 65% to 100% of B in 5 min. The T splitter resulted in a flow-rate of 0.20 
mL/min towards the diode array detector and 0.10 mL/min towards the ESI source. During the 
first 5 min of separation, the eluate was diverted to waste to avoid instrument damage due to 
the high salt concentration. The photodiode array detector was set at 214 and 276 nm. Mass 
spectra were collected every 3 ms in the positive ion mode. The MS spray voltage was 5.0 kV, 
and the capillary temperature was 260 °C. 
High-resolution HPLC-ESI-MS/MS experiments were performed on a LTQ Orbitrap XL 
apparatus, using the same eluents as for the HPLC-ESI-MS analysis. The applied gradient was: 
0-4 min 5% B, 4-38 min from 5% to 50% B (linear), 38-41 min from 50% to 90% B (linear), at 
a flow rate of 80 µL/min. MS/MS spectra were collected in data dependent scan mode with a 
capillary temperature of 250° C, a source voltage of 3.6 kV and a capillary voltage of 40 V. 
Measurements were performed in the positive ion mode and mass accuracy (FT) was calibrated 
before measurements. Ions were isolated with a width of 6–10 m/z and activated for 30 ms 
using 35% normalized collision energy and an activation q of 0.25. 
Characterization of salivary peptides and proteins 
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Proteins (salivary acidic proline-rich proteins, histatins, salivary cystatins, statherin, proline-
rich peptide P-B, -defensins 1-4, cystatins A, B, C, beta-thymosins (4 and 10), S100A7 (D27), 
S100A8, S100A9, and S100A12 proteins) and several derivatives (acetylated, cysteinylated, 
glutathionylated, phosphorylated, and oxidized forms) have been already identified in our 
previous studies (13-21)	 Experimental mass values were obtained by deconvolution of 
averaged ESI-MS spectra automatically performed using MagTran 1.0 software (22). 
Experimental and theoretical average mass values, available at the Swiss-Prot Data Bank 
(http://us.expasy.org/tools), are reported in Table 1.  
Cystatin C and its oxidized derivative were confirmed in the present study by high resolution 
HPLC-ESI-MS/MS analysis of trypsin digestion products. Semi-purified fractions of cystatin C 
and its derivative were collected at the T-splitter during HPLC-ESI-MS experiments and 
submitted to digestion using the kit “Trypsin Singles Proteomic Grade” (Sigma-Aldrich) 
according to the manufacturer's instructions. The reaction was stopped after 12 h of incubation 
by acidification with 0.1% TFA (final concentration) and the solution stored at -80°C until the 
analysis. HPLC-ESI-MS/MS data were analyzed by the Proteome Discoverer 1.2 program, 
based on SEQUEST cluster as search engine (University of Washington, USA, licensed to 
Thermo Electron Corp., San Jose, CA, USA) against Swiss-Prot human proteome (March 3rd, 
2011 released; Swiss Prot human complete.fasta; 34,765 non redundant protein sequences). The 
decoy database included the reversed version of the human proteome, and the false discovery 
rate (FDR) was set to 0.01 for identifications. For peptide matching the limits were Xcorr 
scores greater than 1.5 for singly charged ions and 2.0 and 2.5 for doubly and triply charged 
ions, respectively, one missed cleavage site. 
Precursor mass search tolerance was set to 10 ppm and fragment mass tolerance was set to 0.8 
Da. Different searches were carried out to determine post-translational modifications (PTMs). 
Peptide sequences and sites of covalent modifications were also validated by manual spectra 
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annotation. The results of HPLC-ESI-MS/MS experiments (Supplemental Table S1) and 
annotated spectra are reported in the Supplemental Material. Our data were in agreement with 
the results of Ryan et al. (23) that demonstrated by a top-down approach that the mature form 
of cystatin C contains 120 amino acids and includes two disulfide bonds. In our samples the 
presence of a naturally occurring methionine sulfoxide derivative of cystatin C was also 
demonstrated for the first time.    
Quantification 
Quantification was based on the area of the low resolution RP-HPLC-ESI-MS eXtracted Ion 
Current (XIC) peaks, and considered when the S/N ratio was at least 5. The XIC analysis 
selectively reveals a protein in the chromatographic profile by extracting the ion current 
associated with the multiply-charged ions characteristic of the protein. The area of the XIC 
peaks is proportional to the peptide/protein concentration under constant analytical conditions 
(24). The ions used to quantify the proteins/peptides were carefully selected to exclude values 
in common with other co-eluting proteins, and they are reported in the Supplemental Table S2. 
A window of ± 0.5 Da was used to extract ion chromatograms.  
Data Analysis 
The software GraphPad Prism (version 4.0) was used for statistical analysis. Ranges, medians, 
means, standard deviations, and standard errors were calculated for all the peptide/protein XIC 
peak area. Means and standard deviations are reported in Table 2. To compare the groups we 
used the opportune statistical test taking into account the distribution of the data (normal or 
skewed) and the variances (homogeneous or unequal). According to these characteristics the 
tests used were the following: parametric t-test (variance homogeneous); t-test with Welch 
correction (normal distribution, variance unequal) and the non-parametric Mann-Whitney test 
(skewed distribution, variance unequal). Statistical analysis was considered significant when 
the p value was less than 0.05 (two-tailed). 
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Results  
Unstimulated whole saliva was rapidly collected and treated with aqueous TFA to reduce 
protein degradation by oral proteinases after collection, and only the acidic soluble fraction was 
considered for the RP-HPLC-ESI-MS investigation. The salivary proteins and peptides 
detected and quantified are reported in Table 1, and their chromatographic position is shown in 
Fig. 1. Characterization of these proteins, mainly based on the RP-HPLC-ESI-MS and 
Tandem/MS analysis, has been previously described by some of us (13-21). Cystatin C and its 
sulfoxide derivative on methionine 14 were confirmed in the present study by high resolution 
HPLC-ESI-MS/MS analysis of trypsin digestion products and data are reported in 
Supplemental Table S1. The level of peptides and proteins under study, established on the basis 
of the extracted ion current peak area, is reported in Tables 2 and 3. Since it is known that the 
level of some salivary proteins and peptides is age-dependent (25), and in particular that bPRPs 
are not fully expressed until after the pubertal age, we excluded bPRPs from our analyses and 
divided the subjects in the following two age groups: 10-17 years and 18-50 years.  
Differences in the salivary levels of aPRPs, cystatins and P-B peptide.   
In agreement with the already reported increase of salivary concentration of aPRPs with age  
(25) the comparison between the 10-17 yrs and the 18-50 yrs control groups (Table 2) resulted 
in a statistically significant difference of the level of the major isoforms of aPRPs, namely 
diphosphorylated PRP-1 type (p value 0.002) and PRP-3 type aPRPs (p value 0.0002), as well 
as of the peptide PC which is generated from PRP-1 type proteins by proteolytic cleavage 
before secretion (p value 0.0001). Unlike controls, aPRPs concentration was only slightly 
affected by age in the DS subjects. This different behavior resulted in a statistically significant 
lower concentration of aPRPs in the 18-50 yrs patients with respect to control group (p value 
0.001 and 0.01, respectively). Even more significant was the difference observed in the levels 
of salivary cystatins S, S1, S2, and SN, which were lower in saliva of the 18-50 yrs patients 
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with respect to control group with the same age (p value <0.001, Table 2). Also this result 
originated from the significant increase of cystatin concentration with age in the controls (p 
values <0.004). Interestingly, cystatin SA did not show a quantitative variation with age, and its 
level was significantly lower in patients than in controls of both age-groups (p value 0.004 and 
0.002, respectively). Cystatin B was detected in two different isoforms: dimeric and 
glutathionylated. Only the salivary concentration of dimeric cystatin B was found significantly 
lower in the oldest DS subjects with respect to the corresponding control group (Table 3). 
Cystatin C showed a statistically significant higher concentration in the 18-50 yrs with respect 
to the 10-17 yrs control group, but not in DS subjects (Table 3). The difference may be 
attributed to an increase with age of the oxidized form in the DS subjects; the same was also 
observed for S100A9 short isoform (see below).  
As observed for the other salivary proteins with glandular secretion origin, P-B peptide 
concentration increased significantly with age in control subjects (p value <0.0001). Moreover, 
the peptide was found significantly more concentrated in saliva of the young patients with 
respect to controls. However, this result may reflect the high variability of peptide 
concentration in the control group.  
Antimicrobial peptides: histatins and -defensins.  
The antimicrobial peptides histatins 3 and 5 (the peptide of the histatin family with higher 
antimicrobial activity) showed similar salivary levels in the 10-17 yrs patient and control 
groups (Table 2), but the increase in concentration with age in the patients, even not 
statistically significant, resulted in a significant difference between DS subjects and controls (p 
value 0.02 for both histatins). A similar behavior was observed for -defensins 1, 2 and 3, that 
showed a trend to increase with age in DS subjects. This was most significant for -defensins 1 
and 2 (p value 0.03 for both), but not in controls (Fig. 2, Table 3). Thus, the levels of the -
defensins 1-3 increase in the 18-50 yrs patient group with respect to controls (p value < 0.006).   
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S100A family proteins and thymosin 4 
Several proteins belonging to the family of S100A were detected and quantified in saliva of the 
subjects affected by Down syndrome; they were S100A7 (D27), S100A8, S100A9, and 
S100A12. In the 10-17 yrs patient group, S100A7 (D27) was detected in all the samples (Fig. 
3), while it was present only in 14 samples of the 18-50 yrs group. In the youngest patient 
group S100A7 (D27) was the most represented member of the S100A family proteins, together 
with S100A9 that was detected in the following different isoforms: short, short phosphorylated 
(at Thr-108 residue), and long S-glutathionylated at the Cys-2 residue (26). Part of the S100A9 
short forms were oxidized at Met-89 residue (19). A comparison between 18-50 yrs DS 
subjects and controls showed a statistically significant different level of both S100A9 short 
phosphorylated and non-phosphorylated isoforms (p values 0.04 and 0.05, respectively). The 
difference was mainly due to the increase with age of the corresponding oxidized derivatives in 
the DS subjects. Differently, the levels of S100A9 long glutathionylated were not affected by 
the age. DS subjects showed a lower level of phosphorylated S100A9 short isoforms with 
respect to controls, even if the difference has not been demonstrated to be statistically 
significant.   
S100A8 was rarely detected in the controls and in the young patients. The frequency was 
highest in the 18-50 yrs patient group (10 out of 18 samples, Fig. 3), that showed a significantly 
increased level of S100A8 with respect to matched controls (p value 0.02). A similar behavior 
was observed for S100A12 protein (Fig. 3); namely it was rarely detected in the controls, and 
found to increase in the 18-50 yrs DS subject group (p value 0.002). Since S100A12 was 
undetected in all the samples of 10-17 yrs control group it was not possible to perform a 
statistical analysis for comparison with the corresponding DS group (Fig. 3). 
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Thymosin 4 salivary concentration increased with age both in DS subjects and controls, but 
the increase was less significant in the former. Nonetheless, no significant differences were 
found between DS subjects and controls.   
 
Discussion 
A proteomic investigation of saliva of DS subjects revealed several interesting differences with 
respect to control subjects. The increase in concentration with age of the major salivary 
proteins of glandular origin, seen in healthy subjects and confirmed by the present data, was not 
observed in the DS subjects. Interestingly, in a previous study Chaushu et al. (27) showed the 
statistically significant reduction of parotid gland salivary secretion in subjects with DS 
compared with a healthy control group. Moreover, the mean flow rate of the older patients was 
found to be decreased by 50% as compared with the younger group, demonstrating a decrease 
in stimulated parotid saliva flow rate across the adult age spectrum in these subjects, differently 
from control group. The authors suggested that a possible explanation for the decline of the 
salivary secretion in the older subjects with DS could be the occurrence of age-related 
neuropathological changes, consistent with Alzheimer's disease (AD). Indeed, a longitudinal 
study on oral health in subjects with AD demonstrated that salivary flow rates decreases in 
these subjects (28). It has been shown that DS is associated with early development of dementia 
(29), and it has also been suggested that oxidative stress could play a role in the pathogenesis of 
the clinical features of DS (30). As a result of over expression of SOD1 encoded by genes on 
chromosome 21 in DS, there is an imbalance of the ratio of anti-oxidant enzymes Cu-Zn 
superoxide dismutase, glutathione peroxidase and catalase which results in oxidative damage of 
different molecules and might be related to the degree of intellectual disability, premature aging 
and dementia observed in DS (31-33). Interestingly, it has been observed recently that 
overexpression of amyloid  (A) protein, whose gene is located on chromosome 21, may be at 
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the basis of the susceptibility to oxidative stress observed in DS subjects (34). Indeed, it has 
been demonstrated that A protein induces mitochondrial oxidative stress, suggesting a novel 
pro-oxidant role for A protein which may be relevant in AD and DS disease pathologies (34).  
Most likely oxidative stress conditions are also responsible for the increase of concentration in 
the DS subjects of methionine sulfoxide derivatives of cystatin C and S100A9. Methionine 
oxidation of cystatin C has been already characterized in the recombinant protein expressed in 
E. coli by Berti et al. (35). The same authors demonstrated that oxidation does not affect the 
structure of the protease-binding region, and thus the interaction with substrates.  
Oxidation of S100A9 has been already detected in saliva from children affected by type 1 
diabetes (19). Sroussi et al. (36) reported that in the healthy mucosal tissue, expression of 
S100A9 by the epithelium may serve to inhibit leukocyte recruitment, and observed that 
oxidation of S100A9 abolished the chemo-repulsive effect on peripheral neutrophils, 
concluding that S100A9 serves as a molecular switch for oxidative control of inflammation 
regulated by its oxidative alteration. Oxidized Met63, Met81, and Met94 were also found to be 
variously present in S100A9 from asthmatic sputum by Gomes et al. (37). According to these 
authors, finding of oxidized S100A9 in a human inflammatory condition supports the notion of 
its oxidant scavenging capacity in vivo.  
The most interesting differences observed between DS subjects and controls concerned the 
levels of S100A7, S100A8 and S100A12 proteins. Interestingly in a recent study, Qin et al. 
(38) identified and characterized by proteomic approaches the protein S100A7 in the CSF and 
brain of Alzheimer’s disease. The authors demonstrated that S100A7 content was elevated in 
the cerebrospinal fluid (CSF) of AD dementia cases compared to neurological control cases, 
and these elevated S100A7 levels selectively identified AD clinical severity, concluding that 
S100A7 could be an early biomarker of AD. They also hypothesized that changes in S100A7 
levels in the CSF of AD patients may reflect the oxidative stress changes, and thus they could 
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be explored to monitor oxidative stress changes associated to altered A metabolism in AD 
(39). In this study we found that salivary concentration of S100A7 is significantly higher in 
Down syndrome subjects with respect to controls, but we did not observe a significant increase 
of the protein level with the age.  
Conversely, the salivary concentration of S100A12, and in particular the frequency of 
observation, significantly increased in DS subjects with age. S100A12 is a potent 
chemoattractant for monocytic cells (40), and it activates various cell types by binding the 
receptor for advanced glycosylation end products (RAGE), a multiligand member of the 
immunoglobulin superfamily of cell surface molecules, inducing expression of adhesion 
molecules and pro-inflammatory cytokines (41). It has been reported that the RAGE pathway is 
also involved in amyloidosis (42), and increased RAGE expression has been associated with 
the lesions of AD (43).  
Similarly to S100A12, the frequency of S100A8 also increased with age. The level of all the 
forms of short S100A9 did not change, and age only affected the relative quantity of the 
oxidized and not-oxidized forms, resulting in the increased relative amount of the latter.  
This study was not able to characterize S100B, which is related to neuropathology in brain 
regions, probably due to levels in the salivary fluid being below the sensitivity of the method 
applied (44).  
Interestingly, in the present study we detected only the variant D27 of S100A7. Previously, on 
whole saliva of newborns the isoform E27 was also detected, but in minor quantities with 
respect to the D27 isoform (20). Protein sequence polymorphisms arising from single 
nucleotide polymorphisms has been also shown for other human salivary proteins, i.e. P-C 
peptide (45), cystatins (23) and several bPRPs (46-48). The top-down proteomic approach 
applied in this study offers the advantage to contemporaneously control a great number of 
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peptide/proteins and characterize specific polymorphisms and unusual PTMs, which could be 
connected in different ways to pathological conditions.  
Even though it has been reported an impaired function of neutrophils in DS subjects, our study 
showed the higher levels of the antimicrobial -defensins 1-3 with respect to controls. A 
contribution to this result may derive from the reported relationship between S100A7 and -
defensins. In fact, Zheng et al. demonstrated that S100A7 enhances messenger RNA expression 
of -defensins 1-3 and induces their extracellular release (49). 
On the whole the results of the present investigation confirm that the use of saliva for 
diagnostic and prognostic purposes is promising. The different concentration of several salivary 
peptides recognized as important biomarkers of different pathologies and in particular of some 
complications of DS confirms that saliva, a simply and not invasively collectable biofluid, may 
reflect systemic disorders. As the lifespan for those with DS continues to increase, the ability to 
prevent or delay the progression of neurodegenerative diseases will promote healthy aging and 
improve quality of life DS subjects.  
 
Acknowledgments 
The authors acknowledge the financial support of Cagliari University, Catholic University of 
Rome, MIUR, Italian National Research Council (CNR), Regione Sardegna and Nando Peretti 
Foundation. 
 
 
 
 
 
 
Top-down proteomics of saliva from Down syndrome subjects  


References 
1. Hill, D.A., Gridley, G., Cnattingius, S., Mellemkjaer, L., Linet, M., Adami, H.O., Olsen, 
J.H., Nyren, O., Fraumeni, J.F. (2003) Mortality and cancer incidence among individuals 
with Down syndrome. Arch. Intern. Med 163, 705–711
2. Barnett, M.L., Press, K.P., Friedman, D., Sonnenberg, E.M. (1986) The prevalence of 
periodontitis and dental caries in a Down's syndrome population. J. Periodontol 57, 288-
293
3. Shapira, J., Stabholz, A., Schurr, D., Sela, M., Mann, J. (1991) Caries levels, Streptococcus 
mutant counts, salivary pH, and periodontal treatment needs of adult Down syndrome 
patients. Spec. Care Dentist. 11, 248-251
4. Cichon, P., Crawford, L., Grimm, W.D. (1998) Early-onset periodontitis associated with 
Down's syndrome - clinical interventional study. Ann. Periodontol 3, 370-380 
5. Gorr, S.U. (2012) Antimicrobial peptides in periodontal innate defense. Front. Oral Biol. 
15, 84-98 
6. Deas, D.E., Mackey, S.A., McDonnell, H.T. (2003) Systemic disease and periodontitis: 
manifestations of neutrophil dysfunction. Periodontol. 2000 32, 82-104
7. Izumi, Y., Sugiyama, S., Shinozuka, O., Yamazaki, T., Ohyama, T., Ishikawa, I. (1989) 
Defective neutrophil chemotaxis in Down's syndrome patients and its relationship to 
periodontal destruction. J. Periodontol. 60, 238-242 
8. Yavuzyilmaz, E., Ersoy, F., Sanal, O., Tezcan, I., Ercal, D. (1993) Neutrophil chemotaxis 
and periodontal status in Down's syndrome patients. J. Nihon Univ. Sch. Dent. 35, 91-95 
9. Søhoel, D.C., Jonsson, R., Johannessen, A.C., Nilsen, R. (1995) Gamma/delta T 
lymphocytes in marginal periodontitis in patients with Down's syndrome. Adv. Exp. Med. 
Biol. 371B, 1135-1136
Top-down proteomics of saliva from Down syndrome subjects  


10. Bachrach, G., Chaushu, G., Zigmond, M., Yefenof, E., Stabholz, A., Shapira, J., Merrick, 
J., Chaushu, S. (2006) Salivary LL-37 secretion in individuals with Down syndrome is 
normal. J. Dent. Res. 85, 933-936 
11. Coburn, S.P., Seidenberg, M., Smith, C.E., Mertz, E.T. (1967) Nonprotein nitrogenous 
metabolites in saliva in Down's syndrome. J. Dent. Res. 46, 1476 
12. Cutress, T.W. (1972) Composition, flow rate and pH of mixed and parotid salivas from 
trisomic 21 and other mentally retarded subjects. Arch. Oral. Biol. 17, 1081-1094 
13. Inzitari, R., Cabras, T., Onnis, G., Olmi, C., Mastinu, A., Sanna, M. T., Pellegrini, M., 
Castagnola, M., Messana, I. (2005) Different isoforms and post-translational modifications 
of human salivary acidic proline-rich proteins. Proteomics  5, 805-815  
14. Castagnola, M., Inzitari, R, Rossetti, D. V., Olmi, C., Cabras, T., Piras, V., Nicolussi, P., 
Sanna, M. T., Pellegrini, M., Giardina, B., and Messana, I. (2004) A cascade of 24 Histatins 
(Histatin 3 fragments) in human saliva: suggestions for a pre-secretory sequential cleavage 
pathway. J. Biol. Chem. 279, 41436–41443 
15. Pisano, E., Cabras, T., Montaldo, C., Piras, V., Inzitari, R., Olmi, C., Castagnola, M., 
Messana, I. (2005) Peptides of human gingival crevicular fluid determined by HPLC-ESI-
MS. Eur. J. Oral. Sci. 113, 462-468 
16. Lupi, A., Messana, I., Denotti, G., Schininà, M. E., Gambarini, G., Fadda, M. B., Vitali, A., 
Cabras, T., Piras, V., Patamia, M., Cordaro, M., Giardina, B., and Castagnola, M. (2003) 
Identification of the human salivary Cystatin complex by the coupling of high-performance 
liquid chromatography and ion-trap mass spectrometry. Proteomics 3, 461–467
17. Inzitari, R., Cabras, T., Rossetti, D. V., Fanali, C., Vitali, A., Pellegrini, M., Paludetti, G., 
Manni, A., Giardina, B., Messana, I., Castagnola, M. (2006) Detection in human saliva of 
different statherin and P-B fragments and derivatives. Proteomics 6, 6370–6379 
Top-down proteomics of saliva from Down syndrome subjects  



18. Inzitari, R., Cabras, T., Pisano, E., Fanali, C., Manconi, B., Scarano, E., Fiorita, A., 
Paludetti, G., Manni, A., Nemolato, S., Faa, G., Castagnola, M., Messana, I. (2009) HPLC-
ESI-MS analysis of oral human fluids reveals that gingival crevicular fluid is the main 
source of oral thymosins beta(4) and beta(10). J. Sep. Sci. 32, 57-63
19. Cabras, T., Pisano, E., Mastinu, A., Denotti, G., Pusceddu, P.P., Inzitari, R., Fanali, C., 
Nemolato, S., Castagnola, M., Messana, I. (2010) Alterations of the salivary secretory 
peptidome profile in children affected by type 1 diabetes. Mol. Cell. Proteomics 9, 2099-
108.   
20. Castagnola, M., Inzitari, R., Fanali, C., Iavarone, F., Vitali, A., Desiderio, C., Vento, G., 
Tirone, C., Romagnoli, C., Cabras, T., Manconi, B., Sanna, M.T., Boi, R., Pisano, E., 
Olianas, A., Pellegrini, M., Nemolato, S., Heizmann, C.W., Faa, G., Messana, I. (2011) The 
surprising composition of the salivary proteome of preterm human newborn. Mol. Cell. 
Proteomics 10, M110.003467. 
21. Cabras, T., Manconi, B., Iavarone, F., Fanali, C., Nemolato, S., Fiorita, A., Scarano, E., 
Passali, G.C., Manni, A., Cordaro, M., Paludetti, G., Faa, G., Messana, I., Castagnola, M.  
(2012) RP-HPLC-ESI-MS evidenced that salivary cystatin B is detectable in adult human 
whole saliva mostly as S-modified derivatives: S-glutathionyl, S-cysteinyl and S-S 2-mer. 
J. Proteomics 75, 908-913.
22. Zhang, Z., Marshall, A.G. (1998) A universal algorithm for fast and automated charge state 
deconvolution of electrospray mass-to-charge ratio spectra. J. Am. Soc. Mass Spectrom. 9, 
225-233
23. Ryan, C.M., Souda, P., Halgand, F., Wong, D.T., Loo, J.A., Faull, K.F., Whitelegge, J.P. 
(2010) Confident assignment of intact mass tags to human salivary cystatins using top-
down Fourier-transform ion cyclotron resonance mass spectrometry. J. Am. Soc. Mass 
Spectrom. 21, 908-17 
Top-down proteomics of saliva from Down syndrome subjects  


24. Ong, S. E., and Mann, M. (2005) Mass spectrometry-based proteomics turns quantitative. 
Nat. Chem. Biol. 1, 252–262 
25. Cabras, T., Pisano, E., Boi, R., Olianas, A., Manconi, B., Inzitari, R., Fanali, C., Giardina, 
B., Castagnola, M., Messana, I. (2009) Age-dependent modifications of the human salivary 
secretory protein complex. J Proteome Res. 8, 4126-4134. 
26. Castagnola, M., Cabras, T., Iavarone, F., Fanali, C., Messana, I. (2013) Calcium-Binding 
Proteins and RAGE: from Structural Basics to Clinical Applications. Detection of Ca2+-
binding S100 Proteins in Human Saliva by HPLC-ESI-MS, Heizmann C.W. Editor, pp. 
357-372, Humana Press.  
27. Chaushu, S., Becker, A., Chaushu, G., Shapira, J. (2002) Stimulated parotid salivary flow 
rate in patients with Down syndrome. Spec. Care Dentist 22, 41-44 
28. Ship, J.A., Puckett, S.A. (1994) Longitudinal study on oral health in subjects with 
Alzheimer’s disease. J. Am. Geriatr.Soc. 42, 57-63  
29. Roizen, N.J., Patterson, D. (2003) Down's syndrome. Lancet 361,1281–1289 
30. Dickinson, M.J., Singh, I. (1993) Down's syndrome, dementia, and superoxide dismutase. 
Br. J. Psychiatry 162, 811–817
31. Jovanovic, S.V., Clements, D., MacLeod, K. (1998) Biomarkers of oxidative stress are 
significantly elevated in Down syndrome. Free Radic. Biol. Med. 25, 1044–1048. 
32. de Haan, J.B., Susil, B., Pritchard, M., Kola, I. (2003) An altered antioxidant balance occurs 
in Down syndrome fetal organs: implications for the “gene dosage effect” hypothesis. J. 
Neural Transm. Suppl. (67), 67–83  
33. Perluigi, M., Butterfield, D.A. (2012) Oxidative Stress and Down Syndrome: A Route 
toward Alzheimer-Like Dementia. Curr. Gerontol. Geriatr. Res. 2012, 724904.  
Top-down proteomics of saliva from Down syndrome subjects  


34. Bartley, M.G., Marquardt, K., Kirchhof, D., Wilkins, H.M., Patterson, D., Linseman, D.A. 
(2012) Overexpression of amyloid- protein precursor induces mitochondrial oxidative 
stress and activates the intrinsic apoptotic cascade. J. Alzheimers Dis. 28, 855-868. 
35. Berti, P.J., Ekiel, I., Lindahl, P., Abrahamson, M., Storer, AC. (1997) Affinity purification 
and elimination of methionine oxidation in recombinant human cystatin C. Protein Expr. 
Purif. 11, 111-118 
36. Sroussi, H.Y., Berline, J., Palefsky, J.M. (2007) Oxidation of methionine 63 and 83 
regulates the effect of S100A9 on the migration of neutrophils in vitro. J. Leukoc. Biol. 81, 
818-824 
37. Gomes, L.H., Raftery, M.J., Xing Yan, W., Goyette, J.D., Thomas, P.S., Geczy, C.L. 
(2012) S100A8 and S100A9-oxidant scavengers in inflammation. Free Radic. Biol. Med. 
doi:pii: S0891-5849(12)01862-X.  
38. Qin, W., Ho, L., Wang, J., Peskind, E., Pasinetti, G.M. (2009) S100A7, a novel Alzheimer's 
disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective 
promotion of ADAM-10. PLoS One 4, e4183 
39. Gustaw, K.A., Garrett, M.R., Lee, H.G., Castellani, R.J., Zagorski, M.G., Prakasam, A., 
Siedlak, S.L., Zhu, X., Perry, G., Petersen, R.B., Friedland, R.P., Smith, M.A. (2008) 
Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J. 
Neurochem. 106, 1350–1356. 
40. Miranda, L.P., Tao, T., Jones, A., Chernushevich, I., Standing, K.G., Geczy, C.L., 
Alewood, P.F. (2001) Total chemical synthesis and chemotactic activity of human 
S100A12 (EN-RAGE). FEBS Lett. 488, 85–90 
41. Hofmann, M.A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., 
Bierhaus, A., Nawroth, P., Neurath, M.F., Slattery, T., Beach, D., McClary, J., Nagashima, 
Top-down proteomics of saliva from Down syndrome subjects  


M., Morser, J., Stern, D., Schmidt, A.M. (1999) RAGE mediates a novel proinflammatory 
axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889–901 
42. Yan, S.D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, 
A.M., Stern, D., Kindy, M. (2000) Receptor dependent cell stress and amyloid 
accumulation in systemic amyloidosis. Nat. Med. 6, 643–651 
43. Sasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y., Takeuchi, M., Makita, 
Z. (2001) Immunohistochemical distribution of the receptor for advanced glycation end 
products in neurons and astrocytes in Alzheimer’s disease. Brain Res. 888, 256–262 
44. Van Eldik, L.J., Griffin, W.S.T. (1994) S100 beta expression in Alzheimer`s disease: 
relation to neuropathology in brain regions. Biochim. Biophys. Acta 1223, 398-403 
45. Halgand, F., Zabrouskov, V., Bassilian, S., Souda, P., Wong, D.T., Loo, J.A., Faull, K.F., 
Whitelegge, J.P. (2010) Micro-heterogeneity of human saliva Peptide P-C characterized by 
high-resolution top-down Fourier-transform mass spectrometry. J. Am. Soc. Mass 
Spectrom. 21, 868-877 
46. Halgand, F., Zabrouskov, V., Bassilian, S., Souda, P., Loo, J.A., Faull, K.F., Wong, D.T., 
Whitelegge, J.P. (2012) Defining intact protein primary structures from saliva: a step 
toward the human proteome project. Anal. Chem. 84, 4383-4395 
47.  Messana, I., Inzitari, R., Fanali, C., Cabras, T., Castagnola, M. (2008) Facts and artifacts in 
proteomics of body fluids. What proteomics of saliva is telling us? J. Sep. Sci. 31, 1948-
1963 
48.  Oppenheim, F.G., Salih, E., Siqueira, W.L., Zhang, W., Helmerhorst, E.J. (2007) Salivary 
proteome and its genetic polymorphisms. Ann. N. Y. Acad. Sci. 1098, 22-50   
49. Zheng, Y., Niyonsaba, F., Ushio, H., Ikeda, S., Nagaoka, I., Okumura, K., Ogawa, H. 
(2008) Microbicidal protein psoriasin is a multifunctional modulator of neutrophil 
activation. Immunology 124, 357–367 
Top-down proteomics of saliva from Down syndrome subjects  


Figure legends 
Figure 1. 
Typical total ion current profile (TIC) of the acidic soluble fraction of whole saliva from Down 
syndrome subjects. The elution ranges of the salivary proteins investigated in the study are 
indicated. 
 
Figure 2. 
Distribution of the XIC peak areas of -defensins 1, 2 and 3 in the two age groups of controls 
and Down syndrome subjects. 
 
Figure 3. 
Distribution of the XIC peak areas of S100A7, S100A8 and S100A12 in the two age groups of 
controls and Down syndrome subjects. 
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Table 1. Elution times, experimental and theoretical average mass values (Da) of the  
proteins and peptides detected and quantified in saliva of DS subjects and controls. 
Protein (Swiss-Prot code) El. time (min) Exp. av mass   (Th. av mass) 
PRP-1 type 2P  (P02810) 22.9-23.6 15,515 ± 2  (15,514-15,515) 
PRP-3 type 2P  (P02810) 23.3-24.2 11,161 ± 1  (11,161-11,162) 
P-C peptide  (P02810) 13.6-14.5 4,370.9 ± 0.4  (4,370.8) 
Histatin 1 (P15515) 23.3-23.8 4,928.2 ± 0.5  (4,928.2) 
Histatin 3  (P15516) 17.6-17.9 4,062.2 ± 0.4  (4,062.4) 
Histatin 5 (P15516) 14.2-14.7 3,036.5 ± 0.3  (3,036.3) 
Histatin 6 (P15516) 14.0-14.4 3,192.4 ± 0.3  (3,192.5) 
Cystatin S nonP (P01036) 37.4-38.2 14,186 ± 2  (14,185.8 ) 
Cystatin S 1P  (S1) 37.7-38.4 14266 ± 2  (14,265.8 ) 
Cystatin S 2P (S2) 37.8-38.4 14,346 ± 2  (14,345.8 ) 
Cystatin SN (P01037) 35.8-36.4 14,312 ± 2  (14,313.1) 
Cystatin SA (P09228) 38.7-39.4 14,347 ± 2  (14,346.1 ) 
Cystatin B dimeric form (P04080) 33.6-34.4 22,362 ± 3 (22,361.2) 
Cystatin B glutathionylated 32.5-33.1 11,487 ± 2 (11,486.7) 
Cystatin C (P01034) 38.2-38.9 13,343 ± 2 (13,343.1) 
Cystatin C methionine sulfoxide 38.1-38.7 13,360 ± 2 (13,359.1) 
Statherin 2P (P02808) 28.9-29.5 5,380.0 ± 0.5 (5,379.7) 
P-B (P02814) 29.7-30.6 5,792.9 ± 0.5 (5,792.7) 
Thymosin 4 (P62328)                             20.7-21.0 4,963.7 ± 0.4 (4,963.5) 
-defensin 1 (P59665) 24.9-25.4 3,442.1 ± 0.4  (3,442.1) 
-defensin 2 (P59665 and P59666)         24.9-25.4 3,371.0 ± 0.4  (3,371.0) 
-defensin 3 (P59666) 24.9-25.4 3,486.1 ± 0.4  (3,486.1) 
S100A7 (D27) (P31151*)  37.4-38.0 11,367 ± 2 (11,367.8) 
S100A8
 
(P05109) 39.1-39.7 10,833 ± 2 (10,834.5) 
S100A9 short 1P (P06702) 41.3-42.0 12,770 ± 2 (12,769.2) 
S100A9 short 1P methionine sulfoxide                                          41.3-42.0 12,786 ± 2 (12,785.2) 
S100A9 short  41.3-42.0 12,690 ± 2 (12,689.2) 
S100A9 short methionine sulfoxide 41.3-42.0 12,707 ± 2 (12,705.2) 
S100A9 long glutathionylated 41.1-41.8 13,458 ± 2 (13,456.8) 
S100A12 (P80511) 39.5-40.2 10,443 ± 2 (10,443.9) 
aThe term PRP-1 type includes the three entire isoforms PRP-1, PRP-2, and Pif-s, with a  
mass difference of 1 Da. The term PRP-3 type includes the truncated isoforms PRP-3,  
PRP-4 and Pif-f.  *The Swiss-Prot code refers to the variant E27.  
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Table 2. Extracted ion current peak areas of salivary proteins/peptides of glandular origin 
determined in DS subjects and healthy controls (mean values ± SD ×108). 
Protein Ctrlsa 
(N=18) 
Patientsa 
(N=18) 
P  
valueb 
Ctrlsc 
(N=18) 
Patientsc 
(N=18) 
P 
valueb 
Ctrlsd 
P value 
Patientsd 
P value 
PRP-1 2P 19.1±13.7 15.2±10.3 ns 40.7±22.8 19.8±8.1 0.001 0.002 ns 
PRP-3 2P 5.5±4.0 7.1±6.1 ns 15.2±9.5 8.4±5.2 0.01 0.0002 ns 
P-C  5.3±4.2 8.4±7.4 ns 13.3±5.7 11.0±10.0 ns 0.0001 ns 
Hst-1 2.9±1.9 2.2±1.8 ns 3.4±2.4 4.8±5.0 ns ns 0.04 
Hst-3 0.7±0.6 0.7±0.8 ns 0.8±1.5 1.6±1.6 0.02 ns ns 
Hst-5 1.7±1.1 3.0±3.3 ns 2.3±2.1 5.3±4.0 0.019 ns ns 
Hst-6 0.8±0.5 0.8±0.9 ns 1.2±2.0 2.2±1.8 ns ns 0.03 
Cyst S 02±0.3 0.1±0.1 ns 0.5±0.4 0.1±0.2 0.0004 0.003 ns 
Cyst S1 2.7±3.9 1.3±1.4 ns 6.6±5.1 1.3±1.7 0.0001 0.002 ns 
Cyst S2 0.8±1.3 0.3±0.5 ns 1.6±1.1 0.4±0.8 0.0002 0.004 ns 
Cyst SN 4.2±6.2 3.5±4.9 ns 12.0±9.2 3.7±6.2 0.001 0.001 ns 
Cyst SA 1.0±0.9 0.2±0.3 0.004 1.4±1.7 0.2±0.3 0.002 ns ns 
Statherin 6.1±4.1 7.8±6.2 ns 9.5±6.1 12.7±12.0 ns ns ns 
P-B  4.1±2.7 9.3±7.1 0.03 14.9±8.3 15.4±13.9 ns <0.0001 ns 
 
a10-17 yrs group; bcontrols vs DS subjects; c18-50 yrs group; d10-17 vs 18-50 yrs group; ns: not 
significant 
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Table 3. Extracted ion current peak areas of other salivary proteins/peptides (mean values ± SD 
×108) and results of the comparison between the groups.  
Protein Ctrlsa 
(N=18) 
Patientsa 
(N=18) 
P  
value 
Ctrlsb 
(N=18) 
Patientsb 
(N=18) 
P 
value 
Ctrlsc 
P value 
Patientsc 
P value 
Cyst B  
dimer 
0.33±0.43 0.23±0.13 ns  0.33±0.19 0.19±0.12 0.01 ns ns 
Cyst B glut 0.24±0.28 0.51±0.45 0.04 0.55±0.53 0.39±0.21 ns 0.03 ns 
Cyst C 0.15±0.23 0.28±0.20 0.02 0.49±0.23 0.33±0.41 0.02 0.0002 ns 
Cyst C 
sulfox 
0.03±0.07 0.11±0.15 ns 0.03±0.09 0.17±0.16 0.004 ns ns 
Cyst C tot* 0.18±0.23 0.39±0.30 0.02 0.52±0.25 0.51±0.45 ns 0.0002 ns 
Thymosin 4 0.15±0.14 0.30±0.31 ns  0.43±0.25 0.61±0.58 ns 0.0003  0.05 
-defensin 1 0.5±0.6 0.9±1.0 ns 0.5±0.4 2.4±2.7 0.006 ns 0.03 
-defensin 2 0.4±0.4 0.7±0.7 ns 0.4±0.3 1.6±1.5 0.003 ns 0.03 
-defensin 3 0.3±0.4 0.4±0.5 ns 0.2±0.2 0.8±0.8 0.004 ns ns 
S100A7 
(D27) 
0.07±0.12 
(5/18) 
0.43±0.55 
(18/18) 
0.0004 0.03±0.10 
(2/18) 
0.28±0.47 
(14/18) 
0.001 ns ns 
S100A8 0.04± 0.1 
(4/18) 
0.14±0.37 
(3/18) 
ns 0.04±0.09 
(4/18) 
0.17±0.17 
(10/18) 
0.02 ns ns 
S100A9 
short 
0.41±0.49 
(12/18) 
0.27±0.36 
(11/18) 
ns 0.39±0.44 
(10/18) 
0.16±0.18 
(12/18) 
0.05 ns ns 
S100A9 
short sulfox 
0.22±0.24 
(11/18) 
0.17±0.22 
(11/18) 
ns 0.11±0.18 
(6/18) 
0.21±0.16 
(14/18) 
0.04 ns ns 
S100A9 
short tot* 
0.63±0.69 
(12/18) 
0.44±0.50 
(15/18) 
ns 0.50±0.52 
(11/18) 
0.37±0.30 
(14/18) 
ns ns ns 
S100A9 1P 
short  
0.26±0.34 
(11/18) 
0.14±0.22 
(10/18) 
ns 0.20±0.27  
(8/18) 
0.06±0.07 
(8/18) 
0.04 ns ns 
S100A9 1P 
short sulfox 
0.11±0.18 
(8/18) 
0.07±0.16 
(6/18) 
ns 0.05±0.11 
(4/18) 
0.11±0.19 
(10/18) 
ns  
  
ns ns 
S100A9 1P 
short  tot* 
0.38±0.47 
(11/18) 
0.22±0.27 
(12/18) 
ns 0.24±0.34 
(8/18) 
0.17±0.22 
(11/18) 
ns ns ns 
S100A9 long 
glut 
0.17±0.35 
(6/18) 
0.19±0.32 
(7/18) 
ns 0.27±0.39 
(8/18) 
0.14±0.18 
(9/18) 
ns ns ns 
S100A12 0 
(1/18) 
0.04±0.13 
(2/18) 
- 0.12±0.34 
(2/18) 
0.34±0.32 
(14/18) 
0.002 - 0.001 
 
a10-17 yrs group; bcontrols vs DS subjects; c18-50 yrs group; d10-17 vs 18-50 yrs group; 
*Oxidized plus not oxidized forms; ns: not significant.  
Top-down proteomics of saliva from Down syndrome subjects  


 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 
 
 
Top-down proteomics of saliva from Down syndrome subjects  


 
 
 
 
 
 
 
 
Fig.2 
 
 
Top-down proteomics of saliva from Down syndrome subjects  



 
 
 
 
 
 
Fig.3 
